FDA grants fast review for AstraZeneca's Tagrisso in early-s...

The FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung cancer.

Price cut wins NICE OK for AZ’s Tagrisso in untreated lung c...

UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement

ASCO 2020 round-up: Virtual conference still delivers the dr...

ASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping moments, reports Richard Staines. This time of year oncologists from

Given after surgery, AZ’s Tagrisso prevents lung cancer comi...

AstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Tagrisso delays the recurrence of EGFR-positive non-smal

Tagrisso trial halted early after ‘overwhelming’ efficacy

A phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib) will be unblinded early after strong results.

AZ’s new cancer drugs drive another stellar quarter